Udo Hoffmann,Michael T. Lu,Borek Foldyna,Markella V. Zanni,Julia Karady,Jana Taron,Bingxue K. Zhai,Tricia Burdo,Kathleen V. Fitch,Emma M. Kileel,Kenneth Williams,Carl J. Fichtenbaum,Edgar T. Overton,Carlos Malvestutto,Judith Aberg,Judith Currier,Craig A. Sponseller,Kathleen Melbourne,Michelle Floris-Moore,Cornelius Van Dam,Michael C. Keefer,Susan L. Koletar,Pamela S. Douglas,Heather Ribaudo,Thomas Mayrhofer,Steven K. Grinspoon,Aleen Khodabakhshian,Amy Sbrolla,Beverly E Sha,Christie Lyn Costanza,Claudia A Hawkins,Connor Reynolds,Cornelius N Van Dam,Dan Berrner,David Choi,Jamie L Nemeth,Jeffrey M Jacobson,Joan Gottesman,John Dwyer,John R Koethe,Jorge L Santana,Julie Pasternak,Ken S Ho,Magdalena E Sobieszczyk,Mark Mall,Moises S Huaman,Quynh Truong,Rebecca Fry,Robert T O'Donnell,Roberto C Arduino,Romina Chinchay Collahua,Shaun Barcavage,Shobha Swaminathan,Sigrid Perez-Frontera,Todd Stroberg,

Abstract:Importance: Cardiovascular disease (CVD) is increased among people with HIV (PWH), but little is known regarding the prevalence and extent of coronary artery disease (CAD) and associated biological factors in PWH with low to moderate traditional CVD risk.Objectives: To determine unique factors associated with CVD in PWH and to assess CAD by coronary computed tomography angiography (CTA) and critical pathways of arterial inflammation and immune activation.Design, Setting, and Participants: This cohort study among male and female PWH, aged 40 to 75 years, without known CVD, receiving stable antiretroviral therapy, and with low to moderate atherosclerotic cardiovascular disease (ASCVD) risk according to the 2013 American College of Cardiology/American Heart Association pooled cohort equation, was part of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), a large, ongoing primary prevention trial of statin therapy among PWH conducted at 31 US sites. Participants were enrolled from May 2015 to February 2018. Data analysis was conducted from May to December 2020.Exposure: HIV disease.Main Outcomes and Measures: The primary outcome was the prevalence and composition of CAD assessed by coronary CTA and, secondarily, the association of CAD with traditional risk indices and circulating biomarkers, including insulin, monocyte chemoattractant protein 1 (MCP-1), interleukin (IL) 6, soluble CD14 (sCD14), sCD163, lipoprotein-associated phospholipase A2 (LpPLA2), oxidized low-density lipoprotein (oxLDL), and high-sensitivity C-reactive protein (hsCRP).Results: The sample included 755 participants, with a mean (SD) age of 51 (6) years, 124 (16%) female participants, 267 (35%) Black or African American participants, 182 (24%) Latinx participants, a low median (interquartile range) ASCVD risk (4.5% [2.6%-6.8%]), and well-controlled viremia. Overall, plaque was seen in 368 participants (49%), including among 52 of 175 participants (30%) with atherosclerotic CVD (ASCVD) risk of less than 2.5%. Luminal obstruction of at least 50% was rare (25 [3%]), but vulnerable plaque and high Leaman score (ie, >5) were more frequently observed (172 of 755 [23%] and 118 of 743 [16%], respectively). Overall, 251 of 718 participants (35%) demonstrated coronary artery calcium score scores greater than 0. IL-6, LpPLA2, oxLDL, and MCP-1 levels were higher in those with plaque compared with those without (eg, median [IQR] IL-6 level, 1.71 [1.05-3.04] pg/mL vs 1.45 [0.96-2.60] pg/mL; P = .008). LpPLA2 and IL-6 levels were associated with plaque in adjusted modeling, independent of traditional risk indices and HIV parameters (eg, IL-6: adjusted odds ratio, 1.07; 95% CI, 1.02-1.12; P = .01).Conclusions and Relevance: In this study of a large primary prevention cohort of individuals with well-controlled HIV and low to moderate ASCVD risk, CAD, including noncalcified, nonobstructive, and vulnerable plaque, was highly prevalent. Participants with plaque demonstrated higher levels of immune activation and arterial inflammation, independent of traditional ASCVD risk and HIV parameters.

HIV Infection and Electrocardiogram Abnormalities: Baseline Assessment from the CHART Cohort

Electrocardiographic Abnormalities among People with HIV in Shanghai, China

Electrocardiographic abnormalities and associated factors among HIV-infected adults on antiretroviral therapy

Differential Genome-Wide Associated Variants and Enriched Pathways of ECG Parameters among People with Versus Without HIV

Age-specific Associations Between HIV Infection and Carotid Artery Intima-Media Thickness in China: a Cross-Sectional Evaluation of Baseline Data from the CHART Cohort.

HIV Infection is Associated with Longer Electrocardiographic QTc Intervals: Baseline Evaluation from the CHART Cohort

Prevalence of echocardiographic abnormalities in HIV-infected adults on long-term combination antiretroviral therapy

Cardiac MRI‐Based Assessment of Myocardial Injury in Asymptomatic People Living With Human Immunodeficiency Virus: Correlation With nadir CD4 Count

Differences in Hypertension and Prehypertension among People Living with and Without HIV in China: Role of HIV Infection and Antiretroviral Therapy

Factors influencing left ventricular diastolic dysfunction on echocardiography of people living with HIV in Kunming, China

The Association and Predictive Ability of ECG Abnormalities with Cardiovascular Diseases: A Prospective Analysis

Carotid Ultrasound Abnormalities of People Living With HIV in Kunming, China: Multiple Correspondence Analysis Approach to Identify Influencing Factors

Cardiac biomarkers can detect and track subclinical HIV-associated myocardial disease in newly diagnosed people living with HIV

Association of insulin resistance and glycemic measures with major abnormal electrocardiogram in older Chinese: cross-sectional analysis based on the Guangzhou Biobank Cohort Study

Higher cardiovascular disease risks in people living with HIV: A systematic review and meta-analysis

Association between the triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular diseases in people living with human immunodeficiency virus: Evidence from a retrospectively cohort study 2005-2022

Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study

Prevalence and patterns of echocardiographic abnormalities among people living with HIV on anti-retroviral therapy in Kumasi, Ghana

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals

HIV, HIV-specific Factors and Myocardial Disease in Women